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Summary: Menopause is characterized by 
depletion of ovarian follicles, a reduction of 
ovarian hormones to castrate levels and elevated 
levels of serum gonadotropins from the anterior 
pituitary gland. Although this process has 
significant repercussions throughout the body 
and affects a large proportion of our society, the 
neuroendocrine control mechanisms that 
accompany menopause are poorly understood. 
This review aims to examine rigorously the 
most accredited literature to provide an update 
about  our current understanding of the role of 
the hypothalamic-pituitary axis in the onset of 
and transition into female reproductive 
senescence, focusing on the role of some 
specific neuropeptides in regulating the HPG 
axis and on their effects on several menopausal 
symptoms, especially referring to the 
cardiovascular risk, to open up new horizons for 
new therapeutic strategies. 
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Menopause is a condition caused by the 
depletion of ovarian function followed by 
cessation of menstrual flow lasting at least 12 
months. Modern medicine has significantly 
prolonged the lifespan of humans and most 
women spend one-third to half of their lifetime 
in post- menopause [1]. During the transition 
from reproductive to non-reproductive years, 
women often experience some psychological, 
somatic, vasomotor, and urogenital symptoms 
which may affect their daily activities [2]. In 
recent years, studies have shown that 
menopausal symptoms may affect health-related 
quality of life [3,4]. Ovarian aging and 
hormonal changes have been consistently linked 
to vasomotor symptoms, such as, hot flashes, 
night sweats, and some urogenital symptoms 
[5]. The causes of other symptoms reported by 
women in the menopausal transition are 
multifaceted ; moreover it is unclear to what 
degree these are related to aging generally or 
other life circumstances corresponding with 
menopause. Recent reports have also linked 
musculoskeletal pain, headaches, depressed 
mood, and perceived stress to menopausal stage 
and changes in reproductive hormones [6]. 
The reproductive neuroendocrine axis in 
postmenopausal women is intact and responds 
robustly (intensely) to the removal of ovarian 
hormones.  
In primates, menopause is the signal of the 
complete collapse of ovarian function [7].  
Decreased ovarian function is accompanied by 
the loss of circulating estradiol and 
progesterone, reduced steroid feedback and 
signaling to hypothalamic areas that modulate 
gonadotropin releasing hormone (GnRH) 
production and release and increased pituitary 
gonadotropin levels (FSH and LH) [8]. 
The gonadotropin releasing hormone (GnRH) 
system is the primary hypothalamic regulator of 
reproduction and extensive studies have 
demonstrated the role of the GnRH system in 
age-related reproductive failure. 
This review wants to underline the role of 
kisspeptin, neurokinin B (NKB), calcitonin gene 
related peptide (CGRP) and several other 
neuropetides in female reproductive aging and 
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some menopausal symptoms, mediating 
negative steroid feedback within the HPG axis 
and directly acting on different organs and 
tissues throughout the body. 
 
 
2- Materials and methods 
 
This review includes medical papers published 
in the English language since 1990 about the 
relationship between estrogens, some 
neuropeptides and HPG axis in pre, peri and 
postmenopausal women and their supposed role 
in menopausal symptoms, making particular 
reference to their effects on nasal mucosa and 
cardiovascular risk. All pertinent articles have 
been identified through a MEDLINE, PMC and 
EMBASE search and then reports have 




3-HPA axis in human female reproductive 
aging: role of GnRH and neuropeptides 
 
Despite the continued aging of the central 
nervous system, there is compelling evidence 
that many aspects of reproductive 
neuroendocrine function remain intact after 
menopause. 
After the menopause, there are age-related 
changes in the reproductive neuroendocrine 
axis: studies using indirect pharmacological 
methods provide evidence that GnRH secretion 
is increased in postmenopausal women 
compared to premenopausal women [9]. 
Importantly, the ability of estrogen feedback to 
decrease GnRH secretion and gonadotropin 
secretion is not diminished by age [10,11].  
The hypothalamus has been shown to be the 
major site of steroid negative feedback in the 
human [11,12]. 
These studies demonstrate intact hypothalamic 
function in the postmenopausal period and 
indicate that removal of steroid negative 
feedback in postmenopausal women is linked to 
increased GnRH secretion from the 
hypothalamus. Moreover, GnRH mRNA is 
increased in the hypothalamus of 
postmenopausal women, as would be expected 
with removal of steroid negative feedback [13]. 
The elevation of GnRH gene expression occurs 
within a subpopulation of neurons scattered in 
the ventral preoptic region, retrochiasmatic area 
and the infundibular nucleus but not within the 
dorsal preoptic area or septal region [13]. 
Combined with these studies, it has been also 
observed a pronounced enlargement of neurons 
in the hypothalamic infundibular (arcuate) 
nucleus of postmenopausal women [14, 15]. 
This cellular hypertrophy is characterized by 
increased Nissl substance (indicative of 
increased protein synthesis) and enlarged nuclei 
and nucleoli, suggesting increased neuronal 
activity [15, 16]. The neuronal hypertrophy does 
not appear to be a compensatory response to cell 
degeneration because there is neither cell loss 
nor signs of a pathological process in the 
infundibular nucleus of older women [15, 17].  
Hybridization histochemistry studies have 
shown that the hypertrophied neurons express 
estrogen receptor α (ERα) and neurokinin B 
(NKB), kisspeptin (KiSS-1) and other 
neuropeptides’s mRNA and that menopause is 
associated with a striking increase in these 
neuropeptides’s gene expression [16, 17]. 
Remarkably, ovariectomy of young cynomolgus 
monkeys produces identical changes [18], 
providing strong evidence that the hypertrophy 
and increased NKB gene expression in 
postmenopausal women is secondary to the 
ovarian failure of menopause.  
It has been proposed that these hypertrophied 
neurons participate in the hypothalamic circuitry 
regulating estrogen negative feedback, because 
the hypertrophy occurs in a subpopulation of 
Erα mRNA-expressing neurons in concert with 






Studies pioneered by the endocrinologist Selmar 
Aschheim in 1964 showed that ovaries 
transplanted from young female rats with 
normal estrous cycles into old, non-cycling mice 
failed to restore estrous cyclicity, suggesting 
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that the ovary is not the sole determinant of 
female reproductive senescence [20]. In 1972, 
Peng and Huang reported that ovaries harvested 
from old mice and transplanted into young 
ovariectomized mice supported normal estrous 
cycles and formed corpora lutea, whereas 
hypothalamic transplants from old mice into 
young, ovary intact females did not [21].These 
were the first studies to demonstrate clearly that 
exhaustion of ovarian gametes is not the 
exclusive determinant of female reproductive 
aging and they provided the first clue that the 
HPA is involved in female reproductive 
senescence. 
More than four decades ago, Sheehan and 
Kovacs described pronounced differences in 
hypothalamic neuronal morphology between 
pre- and postmenopausal women [22]. The 
neurons were larger in postmenopausal women, 
in a subregion of the infundibular (arcuate) 
nucleus which they named the subventricular 
nucleus [22,23]. The enlarged neurons exhibited 
other signs of hypertrophy, including increased 
nuclear size, larger nucleoli and prominent Nissl 
substance. There was no evidence of increased 
storage material, chromatolysis, swelling or any 
other pathological changes that explained the 
change in neuron size. The hypertrophied 
neurons were identified in women over the age 
of 50 and in women with a history of post-
partum hypopituitarism, but were inconspicuous 
in men of any age [22]. Sheehan proposed that 
the hypertrophy of neurons in postmenopausal 
women was related to loss of ovarian estrogen 
secretion, because the neuronal hypertrophy was 
strongly correlated with uterine atrophy in 
patients with post-partum hypopituitarism [24]. 
Subsequent analysis using computer microscopy 
showed a 30 to 40% increase in the size of 
neurons in the infundibular nucleus of 
postmenopausal women [15,17]. Stereological 
studies revealed no neuronal cell loss in the 
infundibular nucleus of older women [15]. 
Thus, the neuronal hypertrophy is not a 
compensatory response to adjacent neuronal cell 
death. 
The development of in situ hybridization 
allowed characterization of mRNA expression 
in the hypertrophied neurons of postmenopausal 
women.  
The hypertrophied neurons express ERα mRNA 
but do not express GnRH [17]. The increase in 
GnRH gene expression in postmenopausal 
women occurs in a separate subpopulation of 
neurons scattered diffusely in the ventral 
hypothalamus [13]. 
Hybridization of hypothalamic sections with a 
variety of cDNA probes revealed that the 
majority of hypertrophied neurons express, 
kisspeptin, neurokinin B (NKB), substance P 
(SP) and other tachykinins gene transcripts [16]. 
Thus, the hypertrophied neurons express two 
mRNAs that are essential for reproduction, 
NKB and kisspeptin [25, 26, 27].  
Dynorphin mRNA is also expressed in the 
hypertrophied neurons, but unlike the elevation 
of NKB and kisspeptin gene expression in 
postmenopausal women, the expression of the 
mRNA encoding dynorphin is reduced [28]. 
Similar to the human, menopause in monkeys is 
characterized by ovarian failure and 
gonadotropin hypersecretion [29, 30, 31]. 
Quantitative PCR has shown increased 
kisspeptin and kisspeptin receptor mRNA in the 
medial basal hypothalamus of postmenopausal 
monkeys and these changes are duplicated by 
ovariectomy of young rhesus monkeys [32]. 
NKB gene expression is also increased in the 
arcuate nucleus of perimenopausal rhesus 
monkeys with low estrogen levels, and in 
monkeys after long-term ovariectomy [33]. 
Thus, as in women, NKB and kisspeptin gene 
expression is increased in the 
infundibular/arcuate nucleus of aging female 
rhesus monkeys, and these changes are likely 
due to the loss of ovarian steroids. 
 
 
3.2-The KNDy Cells 
 
In 2007 [34], a key observation was made when 
both NKB and kisspeptin, along with a third 
peptide, dynorphin (DYN), were shown to be 
colocalized in a single subpopulation in the 
hypothalamic arcuate nucleus (ARC) of the 
sheep. 
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DYN is an endogenous opioid peptide (EOP) 
that appears to mediate the inhibitory feedback 
control of progesterone on GnRH secretion [35, 
36]. In postmenopausal women, dynorphin 
mRNA is decreased in the infundibular 
(arcuate) nucleus [28], consistent with the 
decrease in dynorphin gene expression reported 
in ovariectomized ewes [36]. In the mouse, 
however, estradiol has been shown to suppress 
dynorphin gene expression in the arcuate 
nucleus [37, 38]. Thus, a single subpopulation 
of neurons in the ARC contains three distinct 
neuropeptides, each of which has been strongly 
implicated in the feedback regulation of GnRH 
neurons; coexistence of multiple peptides in a 
single neuron is a common finding in the central 
and peripheral nervous system [39]. Typically, 
two or more peptides are stored together in large 
dense core vesicles and may be differentially 
released depending on their relative synthesis 
[39]. Changing the balance among the relative 
amounts of peptides could modify the 
reproductive axis. For istance, an increase in the 
gene transcription of excitatory peptides (NKB 
and kisspeptin) combined with a decrease in the 
transcription of an inhibitory peptide 
(dynorphin) could underlie the increased 
gonadotropin secretion in postmenopausal 
women [13,16,28, 40,41]. 
To simplify the reference, the name of this cell 
group has been abbreviated as the KNDy 
(coexpressing kisspeptin, NKB, and DYN) 
subpopulation; each of the component 
neuropeptides (kisspeptin, NKB, and DYN) 
when examined in dual-label studies showed a 
very high degree of colocalization with gonadal 
hormone steroid receptors, specifically the α-
isoform of the estrogen receptor (ERα) [42, 44, 
45, 46], the progesterone receptors (PR) [47] 
and the androgen receptor [48, 49]. 
Although each of these three peptides is found 
in separate sets of neurons in other brain 
regions, recent evidence suggests that the 
colocalization of KNDy peptides seen in the 
ARC is unique among brain regions and is 
conserved across multiple mammalian species 
that include the rat [42], mouse [38], sheep [34] 
and goat [43]. Complementary studies suggest 
that kisspeptin, NKB, and DYN are also 
colocalized in a single subpopulation in the 
human infundibular (ARC) nucleus [40]. These 
anatomical observations strongly suggest that 
KNDy cells constitute a conserved, central node 
in the control of GnRH secretion, playing a key 
role in normal physiological control of 
reproduction as well as in abnormalities leading 
to reproductive endocrine disorders. 
Although we have defined KNDy cells on the 
basis of the presence of three peptides, this 
subpopulation may well contain other 
neurotransmitters as well as other receptors. 
In the case of NKB/kisspeptin/dynorphin 
neurons, that neurotransmitter may be 
glutamate, based on the colocalization of 




3.3-TheKNDy Cellsnetwork in the arcuate 
nucleus and projections to GnRH terminals 
in the median eminence 
 
It’s necessary to show that KNDy cells directly 
contact GnRH neurons to understanding their 
functional role. Because colocalization of the 
three KNDy peptides in the ARC appears to be 
unique among brain areas examined to date, 
colocalization of multiple KNDy peptides in the 
same axon terminal can be used to determine 
the efferent targets of this subpopulation. Using 
this approach, it has been seen that NKB fibers 
project from the arcuate nucleus to both the 
internal and external zones of the median 
eminence, including the lateral palisade zone, a 
site with dense GnRH terminals: KNDy cells 
would provide direct inputs to GnRH neurons in 
the POA as well as in the mediobasal 
hypothalamus (MBH) at the level of their cell 
bodies and dendrites [52, 53]. 
One of the most interesting features of KNDy 
cells is that most appear to receive input from 
other KNDy cells and thus form a reciprocally 
interconnected network within the ARC [42, 47, 
53]: arcuate NKB/kisspeptin/dynorphin neurons 
project extensively within the arcuate nucleus 
and extend across the median eminence to the 
contralateral arcuate nucleus [53]. Within the 
arcuate nucleus there is a dense network of 
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NKB/dynorphin axons and close apposition of 
these axons on NKB/dynorphin cell bodies and 
dendrites, indicative of communication between 
these neurons [42]. It has been hypothesized 
that the KNDy network may play a role in the 
generation of episodic GnRH [38, 54] as well as 
in the coordination/amplification of responses to 
internal and external signals that KNDy cells are 
attuned to (e.g. gonadal steroids). In either case, 
one would predict that appropriate postsynaptic 
receptors to KNDy peptides should also be 
expressed within KNDy cells. Actually, this 
appears to be true for at least two of the three 
KNDy peptide receptors: the high-affinity 
receptor for NKB (NK3R) is colocalized in 
KNDy cells in rats [52], mice [38] and sheep 
[55] and the κ-EOP receptor (KOR), the opioid 
receptor subtype with highest specificity for 
DYN, is expressed within KNDy neurons in the 
mouse [38]. Although the kisspeptin receptor 
(Kiss1r) is expressed predominantly in GnRH 
cells, it is also found in other hypothalamic 
regions but, at least in mice, is not expressed in 
the ARC nucleus, suggesting a lack of 
colocalization within KNDy cells [56]. 
 
 
3.4 - Role in Generation of Episodic GnRH 
Secretion 
 
The observation that KNDy neurons form an 
interconnected network presumably capable of 
producing a synchronous burst of firing has led 
to speculation that they may represent an 
important component of the multiunit activity 
known as the GnRH pulse generator [38, 43]. It 
has been proposed that synchronous activity of 
KNDy neurons is controlled by stimulatory 
actions of NKB and inhibitory actions of DYN 
on these neurons and that their output to GnRH 
neurons is primarily via kisspeptin. Kisspeptin 
neurons express ERa, PR and AR and therefore 
have the potential to relay feedback effects on 
the GnRH neuron [40]. Actually evidence 
suggests that reduced activity of kisspeptin 
neurons in the Arc of rodents, primates and 
sheep is responsible for translating estrogen 
negative feedback to GnRH neurons. OVX 
female and castrated male mice [46, 49], sheep 
[57, 58] and rhesus monkeys [41,59] have an 
increased level of KiSS-1 mRNA in the neurons 
compared with controls. Moreover, if estrogen 
replacement is given to OVX female or 
testosterone is given to castrated male mice, 
sheep and rats, then KiSS-1 mRNA levels are 
reduced to control levels [41, 49, 57, 58,59, 60]. 
This suggests that steroids are negatively 
regulating KiSS-1 mRNA in the Arc, hence 
reducing stimulation of GnRH neurons. Further 
evidence for negative feedback is derived from 
females at the time of menopause, when 
estrogen is low due to reduced follicle numbers 
in humans and rhesus monkeys. At this time, a 
rise in KiSS-1 mRNA and in turn LH is seen 
accompanied by cellular hypertrophy, similar to 
the rise in OVX female rhesus monkey [32, 
40,41], which is thought to be due to the lack of 
negative feedback from the follicles. 
Each GnRH pulse is triggered by an initial 
increase in NKB from a few KNDy neurons, 
which stimulates further NKB release; the 
resulting positive feedback loop produces 
release of kisspeptin onto GnRH neurons and 
hence the extremely rapid increase in GnRH 
secretion that occurs at the onset of a pulse [61]. 
NKB stimulation of KNDy neurons is predicted 
to also stimulate release of DYN, and the 
inhibitory actions of this EOP on KNDy 
neurons first begins to hold kisspeptin release in 
check and, after a few minutes, completely 
suppresses the activity of KNDy neurons, 
terminating the GnRH secretory episode and 
preventing any GnRH secretion between pulses. 
The action of DYN on KNDy neurons will also 
suppress DYN release, which eventually allows 
increased firing and the NKB release that 
triggers the next GnRH pulse. Thus, we 
speculate that kisspeptin in KNDy cells is the 
output that drives GnRH pulses, that NKB is the 
trigger that initiates synchronous firing of 
KNDy neurons and the onset of each pulse, and 
that DYN is the peptide that shuts off the firing 
of KNDy neurons and terminates each pulse 
[62]. Although this model must be rigorously 
tested, it does provide a simple explanation for 
the differential roles of kisspeptin and DYN in 
the negative feedback actions of E2 and 
progesterone, respectively:because kisspeptin 
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release from KNDy neurons is driving GnRH 
release during a pulse, E2 inhibition of 
kisspeptin expression would be expected to 
inhibit GnRH pulse amplitude. In contrast, 
DYN terminates and prevents GnRH secretion 
between pulses. Thus, a stimulation of DYN 
release by progesterone might be expected to 
prolong the interval between pulses and thus 
reduce GnRH pulse frequency. 
There is compelling evidence that changes in 
KNDy cells occur as a part of the process of 
normal aging in association with menopause. 
Specifically, it has long been known that in the 
brains of postmenopausal women, there is 
selective hypertrophy of neurons of the 
infundibular (arcuate) nucleus of the human 
hypothalamus [14]. Rance and colleagues have 
shown in single-label studies that the large 
majority of these hypertrophied neurons each 
contain KISS1[41], NKB [16], and DYN [28] as 
well as ERα [17]mRNA; thus, they likely 
represent KNDy cells of the human 
hypothalamus. In postmenopausal women, there 
is increased gene expression of NKB [16] and 
KISS1[41] in these cells, along with decreased 
gene expression of DYN [28], consistent with 
an alteration in the balance between stimulatory 
(kisspeptin and NKB) and inhibitory (DYN) 
KNDy peptides that would lead to the GnRH 
and LH hypersecretion characteristic of 
postmenopausal women [40]. These changes in 
postmenopausal women are a response to the 
ovarian failure and depletion of ovarian steroids 
that occurs during menopause, because similar 
changes in KNDy peptide gene expression are 
seen in young OVX monkeys [40]. 
 
 
4 – Neuropeptides, estrogens and 
cardiovascular risk in postmenopausal 
women 
 
Cardiovascular disease (CVD), such as coronary 
artery disease (CAD) and hypertension (HTN), 
is more common in men than in premenopausal 
women (Pre-MW) of the same age, suggesting 
cardiovascular benefits of estrogen [63, 64]. 
Epidemiological studies have shown that death 
due to CAD is delayed by ~5 years in Pre-MW 
as compared to men [65]. Moreover, Pre- MW 
are 4–5 times less likely than men to have 
ischemic heart disease [66]. With aging the 
incidence of CVD becomes higher in women 
than in men. The increased risk of CVD in 
postmenopausal women (Post-MW) has been 
linked to the decrease in plasma estrogen levels, 
thus prompting further investigation of the 
effects of estrogen on the cardiovascular system. 
In this section of our review, we want to 
underline a possible role of some neuropepides 
in several menopausal symptoms and, above all, 
their influence on CVD risk in Post-MW, 
starting fromstudies about the relationship 
between nasal symptomatology and function 
and local concentration of estradiol and its 
receptor and neuropeptides (VIP, NPY and SP) 
in postmenopausal women complaining of 
“paradoxical nasal stuffiness” (i.e. sensation of 
nasal blockage without swelling and/or 
anatomical alterations) (Nappi et al., 2003). 
After this study, the effects of menopausal 
status on the content of vasoactive 
neuropeptides in the arterial wall were 
investigated (Di Carlo et al., 2005). 
Then, we analize recent studies about the effect 
of two neuropeptides (CGRP and orexin-A) on 
CVD in post-MW [67, 68] and, at last, the 




4.1 -Nasal mucosa, estrogens and 
neuropeptides in Post-MW 
 
Postmenopausal women often complain of 
reduced nasal function, both in terms of 
olfactive deficit and nasal blockage, even if no 
swelling or morphological alterations can be 
demonstrated  [70]. Elderly subjects show a 
generalized decrease in body water content and 
the degeneration of mucus-secreting cells 
determining a reduced effectiveness of the 
mucociliary system with frequent symptoms of 
nasal stuffiness  [70]. Moreover, recurrent 
epistaxis is also common after the menopause 
[71]. 
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The activity of nasal mucosa in women is 
supposed to be related to variations in sex 
hormones[72,73]. Indeed, different 
histochemical and ultramicroscopical studies of 
this tissue have been performed, observing 
variations during the menstrual cycle [74], 
pregnancy [75], oral contraceptive use [76] and 
after menopause [77].Estrogens may modulate 
nasal mucosa function by affecting the basal 
vasculature and the glandular secretion either 
directly or indirectly by modulating the local 
concentration of neuropeptides and their 
receptors [78]: both vascular tone and glandular 
secretion in the respiratory nasal mucosa are 
controlled by a complex network of regulatory 
neuropeptides. Among these substances, a 
prominent role is exerted by parasympathetic 
peptides, such as vasoactive intestinal peptide 
(VIP), sympathetic peptides, such as 
neuropeptide Y (NPY), and a group of peptides 
released by sensory nerve endings, known as 
sensory neuropeptides, such as substance P (SP) 
[79]. 
Nappi et al. [80] demonstrated that 
postmenopausal hypoestrogenism increases 
vasoconstrictor neuropeptides (NPY) and 
decreases vasodilator neuropeptides (VIP and 
SP) content in nasal mucosa and probably this is 
the trigger for reduced nasal mucosa trophism 
and effectiveness of the mucociliary system 
with consequent paradoxical nasal 
stuffiness.After HRT SP, VIP, E2 and ER was 
significantly increased; therefore both SP and 
VIP seems to be under a positive estrogen 
control at the nasal level. Moreover, a 
significant decrease of NPY was observed after 
HRT. This could support the hypothesis that 
estrogens have an inhibiting effect on NPY at 
the nasal level [81]. In conclusion, HRT might 
exert a positive effect on nasal function in 
postmenopausal women complaining of 
paradoxical nasal stuffiness, that means 
estrogens have positive effects on nasal mucosa, 
directly and indirectly, modulating the local 
concentration of some vasoactive neuropeptides. 
This study has been the starting point to 
investigate the effects of menopausal status on 




4.2 - Neuropeptides content in arterial-wall 
autonomic terminations in Post-MW 
 
Autonomic pathways play a critical role in 
regulating vascular resistance by allowing 
selective redistribution of blood flow to those 
parts which have a greater demand [82]. 
Cathecolamine-synthesizing vasoconstrictor 
neurons also express neuropeptide Y (NPY), 
while autonomic vasodilator neurons, besides 
synthesizing acetilcholine, utilize vasoactive 
intestinal peptide (VIP) and substance P (SP) 
[82]. 
From January 2005–June 2005, Di Carlo et al. 
enrolled 20 premenopausal women (mean age, 
49.7 years) and 20 postmenopausal women 
(mean age, 50.4 years), ≥ 12 months and ≤ 24 
months after menopause, who were undergoing 
abdominal hysterectomy with bilateral 
oophorectomy for benign conditions to evaluate 
the presence of NPY, VIP, SP, E2, estrogen 
receptor α (ERα), and S100 (a generic neuronal 
marker used to assess the content of neuronal 
fibers) in the uterine arteries of pre- and post- 
menopausal women of similar age [83]. In Post-
MW, a reduction in E2 and ERαin the uterine 
artery wall was associated with a decrease in SP 
and VIP, which are vasodilator neuropeptides, 
and with an increase in NPY, which is a well-
known vasoconstrictor peptide [83]. No 
difference in S100 content was observed 
between the two groups so, the differences in 
neuropeptide content were likely the 
consequence of a functional shift, rather than 
being caused by an alteration in the number of 
neuronal fibers [83]. This study suggests that 
postmenopausal hypoestrogenism may cause an 
increase in arterial vascular tone through a 
reduction of vasodilator peptides and an 
increase in vasoconstrictor peptides in the 
arterial-wall termination of the autonomous 
system [83]. These changes in neuropeptide 
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content in the arterial walls might represent a 
new mechanism underlying the negative effects 
of menopause on the cardiovascular system. 
 
4.3 – Role of Calcitonin gene-related peptide 
and orexin-A in CVD risk in Post-MW 
 
4.3a – CGRP and CVD risk in Post-MW 
 
Calcitonin gene-related peptide (CGRP), 
identified in 1982, belong to the calcitonin 
family of neuropeptides which also includes 
adrenomedullin (AM), amylin, intermedin, 
calcitonin and calcitonin receptor-stimulating 
peptide [84]. CGRP is a 37-aminoacid 
neuropeptide with widespread expression such 
as in the heart, blood vessels, pituitary, thyroid, 
lung and gastrointestinal tract and has a wide 
array of biological effects including 
neuromodulation, vasodilatation, cardiac 
contractility, bone growth, and mammalian 
development [84]. Potent subtype selective 
nonpeptide agonists and antagonists for CGRP 
are being developed for therapeutic use in 
hypertension, cardiac failure, migraine 
headaches, Reynaud's syndrome, preeclampsia, 
and diabetes [84]. The role of CGRP to 
influence cardiovascular risk factor in 
postmenopausal women has been recently 
recognized. In one of the studies to determine 
the effects of menopausal status on circulating 
CGRP levels and the correlation between 
circulating CGRP levels and biomarkers for 
CVD, mean circulating CGRP levels were 
compared between Pre-MW and Post-MW: this 
showed CGRP levels higher in the 
postmenopausal women compared with 
premenopausal women [85]. Besides, serum 
CGRP levels positively correlated with serum 
insulin levels. These data show that circulating 
CGRP levels are influenced by menopausal 
status and suggest additional mechanisms 
through which the increased risk of 
hyperinsulinemia and CVD may arise in 
postmenopausal women [85].  
In another study [86], it was observed the 
occurrence of CHD was correlated with high 
homocysteine (Hcy) level and low CGRP level. 
The mean serum CGRP level was significantly 
lower in postmenopausal women with CHD 
than in women without CHD. The mean serum 
Hcy level was significantly higher in CHD than 
in without CHD postmenopausal women. Hcy is 
an independent risk factor of CHD.CGRP, 
estradiol (E(2)) and progesterone (P) are 
independent protective factors of CHD. There 
was no relationship between Hcy, CGRP and 
E(2), and P [87]. 
 
Current evidences of role of molecule CGRP in 
pathophysiology of menopausal symptoms 
really stimulate us further for the assessment of 
role CGRP receptor antagonists such as 
olcegepant and telcagepant in ameliorating 
various postmenopausal symptoms. 
 
 
4.3b –Orexin-A and CVD risk in Post-MW 
 
Orexins A and B (also known as hypocretins 1 
and 2) are recently discovered hypothalamic 
neuropeptides, involved in the regulation of 
feeding behaviour, sleep–wakefulness, and 
neuroendocrine homeostasis [88, 89]. In 
addition to this central role of orexins as 
excitatory neurotransmitters, a putative 
peripheral effect has been suggested after the 
detection of substantial levels of orexins in 
plasma [90] as well as the demonstration of 
orexin receptors in several peripheral tissues, 
including the gastrointestinal tract (GIT), 
endocrine pancreas, adrenal glands, and adipose 
tissue, among others [91, 92]. Recent 
physiological and neuroanatomical studies 
suggest that orexin A may play an important 
role in the control of the hypothalamo–
pituitary–gonadal axis [93] and gonadotropin-
releasing hormone (GnRH) neurons in the 
hypothalamus have been found to be receptive 
to orexin modulation [94]. 
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El-Seedek et al. have reported postmenopausal 
women not on ERT had significantly higher 
plasma orexin-A levels, paralleling the 
significantly lower estrogen levels. Arterial 
blood pressure was also significantly higher in 
this group [68]. It might be speculated that 
orexin A partially mediates this pressor 
response by: increasing basal sympathetic 
activity, causing catecholamine release [95], 
modulating the vasopressin system [96], and 
stimulating renal and adrenal orexin receptors 
[97]. These speculations are further justified by 
the study of Shiraska et al. [98], where 
experimental use of orexin A has been shown to 
increase heart rate, renal sympathetic activity, 
catecholamine release, and mean arterial blood 
pressure. 
Postmenopausal women not receiving ERT had 
significantly higher plasma cholesterol and TG 
levels than reproductive-age women, but, more 
importantly, the levels were also higher than in 
those receiving ERT [68]. Orexins have been 
shown to adversely affect the plasma lipoprotein 
profile [99] and insulin glucose homeostasis, 
and to stimulate insulin release from pancreatic 
cells in vivo and in vitro [100]. 
It is also thought that orexins act in harmony 
with ghrelin, leptin and NPY, among others, to 
control energy balance and metabolism, and 
derangement in any of these can be associated 
with obesity [101]. 
The conclusion is that plasma orexin-A levels 
are elevated after menopause. The association 
between this elevation and hypoestrogenism 
was suggested when normal values were found 
in matched postmenopausal women on ERT. A 
putative causal relationship is suggested 
between increased orexin levels and some of the 
manifestations of the menopausal syndrome, 
notably, an increased cardiovascular risk profile 
so, a possible inhibitory effect of estrogen on 
orexin might partially account for its 




4.4 – HRT and CVD risk in Post-MW 
 
Nowadays, whether menopausal hormone 
therapy (MHT) is beneficial in postmenopausal 
CVD remains controversial [102]. Despite 
reports of vascular benefits of MHT from 
observational and experimental studies, 
randomized clinical trials (RCTs), such as the 
Heart and Estrogen/progestin Replacement 
Study (HERS), the Women’s Health Initiative 
(WHI)and Raloxifene Use for The Heart 
(RUTH)have suggested that, contrary to 
expectations, MHT may increase the risk of 
CVD: in the HERS, almost 3,000 women with 
proven CHD were randomly assigned to MHT 
containing CEE and MPA or placebo. After 4 
years, the frequency of the primary outcome, i.e. 
fatal and non-fatal CHD combined, did not 
differ between the two groups. There was also a 
50%increase in coronary events in the first year 
in the MHT group [103]. The WHI was 
designed to determine fatal and nonfatal heart 
disease, cancer, and osteoporotic fractures as the 
primary outcome. In the estrogen-progestinarm, 
MHT increased risk of heart attacks and strokes. 
CEE alone increased risk of stroke and deep 
vein thrombosis [104]. The RUTH RCT in Post-
MW with CVD or at increased risk of CVD 
demonstrated that raloxifene treatment did not 
change the incidence of coronary events, but 
increased the risk of fatal stroke and venous 
thromboembolism [105,106]. 
Bifulco et al. compared the effects of HRT and 
tibolone on nasal symptomatology/function and 
on local concentrations of estradiol and its 
receptor and neuropeptides (VIP, NPY and SP) 
in postmenopausal women complaining of 
paradoxical nasal stuffiness. All treated patients 
reported an improvement in climacteric 
symptomatology; theevaluation of the 
immunopositivity for E2, estradiol receptor 
(ER), Substance P (SP), Vasoactive Intestinal 
Peptide (VIP) and neuropeptide Y (NPY) 
revealed HRT induced a significant increase in 
E2, ERα, VIP and SP and a decrease in NPY 
immunopositivity. Tibolone determined a 
significant increase in ERα, VIP and SP and a 
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decrease in NPY immunopositivity without any 
action on E2 immunopositivity so, both 
treatments may modulate nasal mucosa function 
through an  action on cholinergic, adrenergic 
and sensory peptides and improve nasal 
function and symptomatology in 
postmenopausal women with paradoxical nasal 
stuffiness. 
On the basis that the alterations seen in nasal 
mucosa of Post-MW with paradoxical nasal 
stuffiness may be a clinical model of the general 
effect of menopausal status on cardiovascular 
system, this study could suggest HRT could 
positively act on CVD risk, modulating the 
levels of vasoconstrictor (NPY) and vasodilator 
neuropeptides (VIP and SP). 
 
 
5 – Discussionsand conclusions 
 
This review demonstrates that a complex 
network between GnRH, FSH, LH, estrogens 
and several neuropeptides plays an important 
role in the transition into female reproductive 
aging and in the pathogenesis of some of the 
main menopausal symptoms (above all, the 
cardiovascular risk in Post-MW).  
Understanding how the synthesis and release of 
individual KNDy peptide is orchestrated within 
KNDy neurons and their projections, and 
ultimately translated into control of the 
reproductive neuroendocrine axis, will likely 
have key relevance for a wide range of issues 
affecting reproductive health and disease. 
Estrogen and other estrogenic compounds have 
significant vasodilator and other beneficial 
vascular effects. Some of the effects of estrogen 
are mediated via vascular ER. As things stand 
now, medical evidence-based guidelines and the 
FDA recommendations are that MHT may be 
used for the relief of moderate to severe 
postmenopausal symptoms, but not for the 
routine prevention of chronic disease conditions 
and primary or secondary Coronary Heart 
Disease (CHD), with the exception that MHT 
may be used conditionally for the prevention of 
osteoporosis when other interventions have been 
considered and are deemed inappropriate. 
Nowadays, very little is known about the effects 
of estrogens on autonomic vasoconstrictor and 
vasodilator neuropeptides at the arterial 
levelThe report of a tight correlation between 
postmenopausal hypoestrogenism and the 
content in arterial-wall autonomic 
terminationsof different vasoactive 
neuropeptides (such as NPY, SP and VIP) open 
up new horizons for the comprehension of the 
biology of menopausal status and for the finding 
of new therapeutic strategies to treat several 
menopausal symptoms and reduce the 
menopausal CVD risk. 
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